Loading…
Sonoma Pharmaceuticals, Inc. is projected to rise to $1.37 by 2027, a +9% move from its current price of $1.26. SNOA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $1.22 | $1.26 | $1.30 | -0.07% |
| Jul 15 | $1.21 | $1.26 | $1.31 | -0.15% |
| Jul 16 | $1.20 | $1.26 | $1.32 | -0.22% |
| Jul 17 | $1.19 | $1.26 | $1.33 | -0.30% |
| Jul 18 | $1.18 | $1.26 | $1.34 | -0.37% |
| Jul 19 | $1.17 | $1.25 | $1.35 | -0.45% |
| Jul 20 | $1.16 | $1.25 | $1.35 | -0.52% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.16 | $1.25 | $1.35 | -0.52% |
| Week 2 | $1.12 | $1.25 | $1.39 | -1.04% |
| Week 3 | $1.09 | $1.24 | $1.42 | -1.55% |
| Week 4 | $1.06 | $1.23 | $1.44 | -2.06% |
| Week 5 | $1.03 | $1.23 | $1.46 | -2.57% |
| Week 6 | $1.01 | $1.22 | $1.47 | -3.08% |
| Week 7 | $0.9921 | $1.21 | $1.49 | -3.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
The company markets Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fissures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacy n60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Sonoma Pharmaceuticals, Inc. (SNOA) is a healthcare company focused on HOCl-based solutions for various care segments and markets globally. It trades at current price $1.25 with a market capitalization of $5.98M and ranks 5186 by market cap.
The price outlook, based on a year-by-year forecast, shows a path of gradual upside from the current level toward higher average prices in the years ahead. The forecast projects an average price of $1.25 in 2026 and $3.49 by 2050, indicating a rising long-run trend underpinned by bullish sentiment in later years.
Key long-run milestones include an average of $1.58 in 2030 and $2.47 in 2040, with a further rise to $3.49 in 2050. These figures imply meaningful upside potential over the multi-year horizon, though they come with inherent uncertainty and are not guarantees.
A major floor 19.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.5% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 122.2% above — clearing it would confirm fresh momentum.
Key SNOA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNOA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.25 | Buy | $1.25 | Buy |
| MA 10 | $1.22 | Buy | $1.22 | Buy |
| MA 20 | $1.18 | Buy | $1.20 | Buy |
| MA 50 | $1.15 | Buy | $1.33 | Sell |
| MA 100 | $1.77 | Sell | $1.73 | Sell |
| MA 200 | $2.68 | Sell | $2.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.02 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 104.73 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 10.53 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.03 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 64.47 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 1.26 | Sell |
| ADX (14) | 14.87 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows a range of $1.01 to $1.55, reflecting recent price motion within that band. RSI14 is at 60, indicating a neutral-to-bullish momentum.
The stock trades around the $1.25 level, with a 50-day simple moving average of $1.15 and a 200-day simple moving average of $2.74. Support is at $1.06 and resistance at $1.25, framing near-term levels to watch over the coming weeks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.01 | $1.26 | $1.43 | 0% | Neutral | |
| $1.08 | $1.37 | $1.83 | +9% | Neutral | |
| $1.12 | $1.46 | $2.03 | +16% | Neutral | |
| $1.11 | $1.48 | $2.13 | +18% | Neutral | |
| $1.15 | $1.56 | $2.30 | +24% | Bullish | |
| $1.02 | $1.42 | $2.14 | +13% | Neutral | |
| $1.02 | $1.45 | $2.22 | +15% | Neutral | |
| $1.09 | $1.57 | $2.46 | +25% | Bullish | |
| $1.20 | $1.76 | $2.80 | +40% | Bullish | |
| $1.35 | $2.01 | $3.25 | +60% | Bullish | |
| $1.51 | $2.41 | $4.15 | +92% | Bullish | |
| $1.90 | $3.44 | $6.51 | +173% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.01 | $1.26 | $1.45 | +0.00% |
| August 2026 | $0.9862 | $1.17 | $1.42 | -7.48% |
| September 2026 | $0.9885 | $1.18 | $1.45 | +0.99% |
| October 2026 | $0.9726 | $1.17 | $1.45 | -0.98% |
| November 2026 | $0.9288 | $1.12 | $1.40 | -3.99% |
| December 2026 | $0.9359 | $1.13 | $1.43 | +1.28% |
Click any year to see its month-by-month SNOA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sonoma Pharmaceuticals, Inc.'s 2026 outlook centres on $1.26, within a $1.01 to $1.43 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SNOA could reach as high as $1.83, with a base case around $1.37 and support toward $1.08 — roughly +9% from $1.26. A consolidation phase looks the most probable path here.
Expect SNOA to range from $1.12 to $2.03 through 2028. The $1.46 average target implies a +16% move from current prices. That is up +6% on the projected 2027 average. Price action looks broadly range-bound.
The SNOA price prediction for 2029 points to an average of $1.48 (low $1.11, high $2.13) — a potential gain of +18% on today's $1.26. A consolidation phase looks the most probable path here.
In 2030, SNOA is projected to trade between $1.15 and $2.30, averaging $1.56 — a potential gain of +24% from today's $1.26. That is up +5% on the projected 2029 average. Momentum favours further upside here.
Sonoma Pharmaceuticals, Inc.'s 2031 outlook centres on $1.42, within a $1.02 to $2.14 range. That is -9% versus the projected 2030 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, SNOA could reach as high as $2.22, with a base case around $1.45 and support toward $1.02 — roughly +15% from $1.26. Price action looks broadly range-bound.
Expect SNOA to range from $1.09 to $2.46 through 2033. The $1.57 average target implies a +25% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SNOA price prediction for 2034 points to an average of $1.76 (low $1.20, high $2.80) — a potential gain of +40% on today's $1.26. Momentum favours further upside here.
In 2035, SNOA is projected to trade between $1.35 and $3.25, averaging $2.01 — a potential gain of +60% from today's $1.26. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sonoma Pharmaceuticals, Inc.'s 2040 outlook centres on $2.41, within a $1.51 to $4.15 range. That is up +20% on the projected 2035 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2050, SNOA could reach as high as $6.51, with a base case around $3.44 and support toward $1.90 — roughly +173% from $1.26. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNOA today (≈ 793.650794 SNOA) could be worth
$2,733.14
+$1,733.14 (+173%) by 2050 · US Dollar
Based on the average projected SNOA price of $3.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNOAwould be worth at today's price.
$1,000 invested in SNOA on Jul 10, 2025 (≈ 253.807103 SNOA) would be worth
$319.8
-$680.2 (-68.0%) today · 0.32× · US Dollar
Based on a SNOA entry price of $3.94 vs. today's $1.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.21 | $1,041.32 | +4.1% |
| 1 month ago | $1.09 | $1,155.96 | +15.6% |
| 3 months ago | $2.28 | $552.63 | -44.7% |
| 6 months ago | $3.43 | $367.35 | -63.3% |
| 1 year ago | $3.94 | $319.8 | -68.0% |
| All time (5.0y) ago | $153.6 | $8.2 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNOA forecast.
Our base-case forecast reaches $2.50 around 2050.
Implied market cap at $2.50: $11.96M
The multi-year forecast portrays a bullish trajectory with rising average prices and expanding upside potential. In 2030, the average price is $1.58, with a min of $1.14 and a max of $2.39, and an ROI of 26.7%, with a BULLISH sentiment.
In 2040, the average price is $2.47, with a min of $1.47 and a max of $4.40, and an ROI of 97.4%, with a BULLISH sentiment. In 2050, the average price is $3.49, with a min of $1.80 and a max of $6.89, and an ROI of 179.5%, with a BULLISH sentiment.
These are estimates, not guarantees, and the path carries uncertainty and risks. The forecast portrays a long-run upswing, but outcomes will depend on a range of market and company-specific factors that are not guaranteed.
Tap a question to reveal the answer.
The 2030 forecast shows min $1.14, avg $1.58, max $2.39 with an ROI of 26.7%, and the sentiment is BULLISH.
The forecast shows increasing average prices and rising ROI through 2030 (ROI 26.7%), with even stronger upside in 2040 (ROI 97.4%) and 2050 (ROI 179.5%), but these are estimates and carry uncertainty.
Yes. The 2030 max is $2.39, which sits above $2, with a min of $1.14 and an avg of $1.58.
Current price is $1.25 and market cap is $5.98M.
RSI14 is 60, SMA50 is $1.15, SMA200 is $2.74, with support at $1.06 and resistance at $1.25; the 30-day range is $1.01 to $1.55, and the sentiment is BULLISH.
Sonoma Pharmaceuticals, Inc. Community Discussion
0Share your Sonoma Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.